Study on the progress of three pathways in anxiety disorders
DOI:
https://doi.org/10.62051/b13xpe52Keywords:
anxiety disorders; the amygdala-prefrontal cortex circuit; the GABAergic pathway; the serotonin pathway.Abstract
An overview is presented in this review, which delves into the neural pathways associated with anxiety disorders. The emphasis is placed on the amygdala and prefrontal cortex circuit, the GABAergic pathway, and the serotonin pathway. The amygdala-prefrontal cortex circuit is essential to processing fear and making decisions; anxiety disorders have been linked to disruption in this circuit. The GABAergic pathway, characterized by the release of GABA and inhibition of neuronal activity, is implicated in anxiety through its role in regulating neuronal excitability. Altered GABAergic function is associated with various anxiety disorders. The serotonin pathway, involving the release of serotonin and modulation of mood and stress responses, is also involved in anxiety disorders. Medications targeting these pathways can help modulate the circuits and alleviate anxiety symptoms. Awareness of these pathways is still limited, though, because anxiety is a complicated illness influenced by a number of factors. The main goals of future research should be the development of individualized treatment plans for anxiety disorders and better clarifying the processes of dysregulation.
Downloads
References
M. V. Fogaça and R. S. Duman, “Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions”, Front. Cell. Neurosci., vol. 13, p. 87. (2019).
El-Gabalawy, R., Mackenzie, C. S., Shooshtari, S., & Sareen, J. “Comorbid physical health conditions and anxiety disorders: A population-based exploration of prevalence and health outcomes among older adults”. General Hospital Psychiatry, 33 (6), 556 – 564. (2011).
Li, M., Santpere, G., Imamura Kawasawa, Y., Evgrafov, O. V., Gulden, F. O., Pochareddy, S., Sunkin, S. M., Li, Z., Shin, Y., Zhu, Y., Sousa, A. M. M., Werling, D. M., Kitchen, R. R., Kang, H. J., Pletikos, M., Choi, J., Muchnik, S., Xu, X., Wang, D., … Li, Z. “Integrative functional genomic analysis of human brain development and neuropsychiatric risks”. Science, 362 (6420), (2018).
D. Datta and A. F. T. Arnsten, “Unique Molecular Regulation of Higher-Order Prefrontal Cortical Circuits: Insights into the Neurobiology of Schizophrenia”, ACS Chem. Neurosci., vol. 9, no. 9, pp. 2127 – 2145. (2018).
W.-Z. Liu et al., “Identification of a prefrontal cortex-to-amygdala pathway for chronic stress-induced anxiety”, Nat Commun, vol. 11, no. 1, p. 2221. (2020).
V. R. Solomon, V. J. Tallapragada, M. Chebib, G. A. R. Johnston, and J. R. Hanrahan, “GABA allosteric modulators: An overview of recent developments in non-benzodiazepine modulators”, European Journal of Medicinal Chemistry, vol. 171, pp. 434 – 461. (2019).
Rocha, L., Alonso-Vanegas, M., MartÃnez-Juárez, I. E., Orozco-Suárez, S., Escalante-Santiago, D., Feria-Romero, I. A., Zavala-Tecuapetla, C., Cisneros-Franco, J. M., Buentello-GarcÃa, R. M., & Cienfuegos, J. “GABAergic Alterations in Neocortex of Patients with Pharmacoresistant Temporal Lobe Epilepsy Can Explain the Comorbidity of Anxiety and Depression: The Potential Impact of Clinical Factors”. Frontiers in Cellular Neuroscience, 8. (2015).
M. Liu et al., “Ulk4 regulates GABAergic signaling and anxiety-related behavior”, Transl Psychiatry, vol. 8, no. 1, p. 43. (2018).
M. J. Zigmond, L. P. Rowland, and J. T. Coyle, “Neurobiology of brain disorders: biological basis of neurological and psychiatric disorders”.
N. Alenina and F. Klempin, “The role of serotonin in adult hippocampal neurogenesis”, Behavioural Brain Research, vol. 277, pp. 49 – 57. (2015).
E. Dale et al., “Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function”, CNS Spectr., vol. 21, no. 2, pp. 143 – 161. (2016).
Gorka, S. M., Young, C. B., Klumpp, H., Kennedy, A. E., Francis, J., Ajilore, O., Langenecker, S. A., Shankman, S. A., Craske, M. G., Stein, M. B., & Phan, K. L. “Emotion-based brain mechanisms and predictors for SSRI and CBT treatment of anxiety and depression: A randomized trial”. Neuropsychopharmacology, 44 (9), 1639 – 1648. (2019).
L. Marwood, T. Wise, A. M. Perkins, and A. J. Cleare, Meta-analyses of the neural mechanisms and predictors of response to psychotherapy in depression and anxiety, Neuroscience & Biobehavioral Reviews, vol. 95, pp. 61 – 72. (2018).
S. J. Brooks and D. J. Stein, A systematic review of the neural bases of psychotherapy for anxiety and related disorders, Dialogues in Clinical Neuroscience, vol. 17, no. 3, pp. 261 – 279. (2015).
B. Dell’Osso, M. Buoli, D. S. Baldwin, and A. C. Altamura, “Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy”, Hum. Psychopharmacol. Clin. Exp., vol. 25, no. 1, pp. 17 – 29. (2010).
R. Polanía, M. A. Nitsche, and C. C. Ruff, “Studying and modifying brain function with non-invasive brain stimulation”, Nat Neurosci, vol. 21, no. 2, pp. 174 – 187. (2018).
M. H. Pollack et al., “Novel treatment approaches for refractory anxiety disorders”, Depress. Anxiety, vol. 25, no. 6, pp. 467 – 476. (2008).
D. S. Pine, S. M. Helfinstein, Y. Bar-Haim, E. Nelson, and N. A. Fox, “Challenges in Developing Novel Treatments for Childhood Disorders: Lessons from Research on Anxiety”, Neuropsychopharmacol, vol. 34, no. 1, pp. 213 – 228. (2009).
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
